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Background: Osteoarthritis (OA) is a multifactorial disease characterized by destruction of the articular cartilage due
to environmental, mechanical and genetic components. The genetics of OA is complex and is not completely
understood. Recent works have demonstrated the importance of microRNAs (miRNAs) in cartilage function. MiRNAs
are a class of small noncoding RNAs that regulate gene expression and are involved in different cellular process:
apoptosis, proliferation, development, glucose and lipid metabolism. The aim of this study was to identify and
characterize the expression profile of miRNAs in normal and OA chondrocytes and to determine their role in the OA.
Methods: Chondrocytes were moved to aggregate culture and evaluated using histological and qPCR techniques.
miRNAs were isolated and analyzed using the Agilent Human miRNA Microarray.
Results: Of the 723 miRNAs analyzed, 7 miRNAs showed a statistically significant differential expression. Amongst
these 7 human miRNAs, 1 was up-regulated in OA chondrocytes (hsa-miR-483-5p) and 6 were up-regulated in
normal chondrocytes (hsa-miR-149*, hsa-miR-582-3p, hsa-miR-1227, hsa-miR-634, hsa-miR-576-5p and hsa-miR-641).
These profiling results were validated by the detection of some selected miRNAs by qPCR. In silico analyses predicted
that key molecular pathways potentially altered by the miRNAs differentially expressed in normal and OA
chondrocytes include TGF-beta, Wnt, Erb and mTOR signalling; all of them implicated in the development,
maintenance and destruction of articular cartilage.
Conclusions: We have identified 7 miRNAs differentially expressed in OA and normal chondrocytes. Our potential
miRNA target predictions and the signalling cascades altered by the differentially expressed miRNAs supports the
potential involvement of the detected miRNAs in OA pathology. Due to the importance of miRNA in mediating the
translation of target mRNA into protein, the identification of these miRNAs differentially expressed in normal and OA
chondrocyte micropellets could have important diagnostic and therapeutic potential. Further studies are needed to
know the function of these miRNAs, including the search of their target mRNA genes, which could lead to the
development of novel therapeutic strategies for the OA treatment.
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Osteoarthritis (OA) is a degenerative joint disease charac-
terized by deterioration in the integrity of hyaline cartilage
and subchondral bone. OA is the most prevalent articular
pathology and the most frequent cause of disability. The eti-
ology for OA is unknown but multiple factors such as obes-
ity, age, anatomic abnormalities, history of joint trauma,* Correspondence: fblagar@sergas.es
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distribution, and reproduction in any mediumjoint instability, repeated injury, overuse and joint dysplasia
are thought to be involved, resulting in severe joint pain,
loss of movement, and irreversible functional disability with
a marked decrease in quality of life [1,2]. This degenerative
process is driven by the activation of the single cell type
present in the mature cartilage, chondrocytes [3]. The inci-
dence of OA is directly related to age and is expected to in-
crease along with the median age of the population.
MicroRNAs (miRNAs) are single-stranded and small
noncoding RNA molecules of 18–24 nt in length that
negatively regulate the expression of target genes in atral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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RNAs, through incomplete base pairing with the 30-
untranslated region (30-UTR) of targets mRNA, to suppress
its gene expression via degradation or translational repres-
sion [4,5]. Depending on the degree of base pairing between
the target mRNAs and the miRNA, the miRNA either cleav-
age the mRNAs (perfect pairing) or repress translation (im-
perfect pairing). Although some algorithms are used to
predict potential mRNA targets, only a few miRNAs have
been validated and assigned to specific mRNAs. These small
RNAs are naturally produced by the cells and they are
derived from primary miRNA transcripts (70 to 100 nt) that
are processed in the nucleus to precursor miRNAs (pre-miR-
NAs) by the ribonuclease Drosha. Later, these pre-miRNAs
are transported into the cytoplasm where they are further
processed into miRNAs by the ribonuclease Dicer. A single
miRNA can regulate the expression of many target genes,
and a target gene can also be regulated by several miRNAs
[6]. These short molecules are conserved from worms to
mammals; this high conservation of miRNAs sequences
highlights the significance of their function. They contribute
to the regulation of a variety of biological functions across di-
verse organisms such as apoptosis, proliferation, differenti-
ation, development, cell cycle, stem cell maintenance,
metabolism and hematopoiesis [6-9]. Recently, specific miR-
NAs were reported to be involved in chondrogenesis and in-
flammatory cartilage diseases [10-15]. A recent work by
Kobayashi et al. [16] demonstrated the role of miRNAs in
cartilage function. These authors showed that Dicer, a critical
enzyme for biogenesis of miRNAs, is essential for normal
skeletal development; since they generated cartilage-specific
Dicer-null mice that showed a greatly decreased chondrocyte
proliferation and accelerated hypertrophy leading to severe
growth defects and premature death of mice [16].
Recent evidences have also indicated that these small
RNA molecules play a role in the pathogenesis of human
disorders such as birth defects and cancer [5], exhibiting
tissue-specific or developmental stage-specific expression
patterns associated with human diseases. Whilst some
studies suggested that miRNA genes account for more
than 1,000 [6], predictive algorithms indicated that more
than a third of all human genes contain putative single or
multiple miRNA recognition elements [9]. MicroRNAs are
encoded all over the genome, in intergenic regions, introns,
exons, exon overlaps, and UTR regions, and approximately
50 % of known human miRNAs are found in clusters [17].
The clustered miRNAs are often related to each other, in
terms of targeting the same gene or different genes in the
same biochemical pathway, but can also be unrelated.
The study of miRNA has become a new field in life
science. The detection of miRNA expression is a very
important first step in miRNA exploration [6]. Current
methodologies have been developed and applied success-
fully in miRNA profiling, including microRNA arrays[6]. The use of microarrays for global characterization of
miRNA expression is becoming an increasingly popular re-
search tool [18,19]. The growing interest in miRNAs has
sparked a natural extension of microarray technology to
screen the expression level of miRNA in parallel [4]. A
number of human diseases are associated with changes in
the copy number or expression of microRNAs, indicating
that miRNA expression levels are closely associated with
developmental and physiological states as well as disease
process [6,8]. Several reports on miRNA profiling human
cartilage [15], cancer [20] and general human tissues [19]
have already been published. The expression profiles of
miRNAs are effective for classification of human cancer
[20], also several published studies showed a probable link
between miRNAs and other human diseases [21], since
microRNA signatures have been associated with well-
defined clinicopathological features and disease outcome
[22]. The potential utility of miRNA expression profiles in
diagnosis and disease monitoring has been investigated and
some studies have postulated the diagnostic and prognostic
utility of circulating RNAs [23]. MiRNA gene signatures
may be more useful and provide more discrimination than
mRNA expression signatures [4]. In some cases it has been
possible to successfully classify poorly differentiated tumors
using the expression profiles of these microARNs while the
mRNA profiles, from the same samples, were not adequate
for this type of classification. Thus it appears that the ex-
pression profiles of miRNA are better than those of mRNA
to classify tumors [20].
However, at present, little is known if aberrant microRNA
expression is associated with OA development. For ex-
ample, miR-146a, miR-155, miR-132 and miR-16 were
found to be up-regulated in rheumathoid arthritis (RA)
patients compared with OA ones [16,24,25]. Moreover, it
was demonstrated that high levels of miR-146 and miR-16
expression were correlated with active disease, whereas low
expression levels correlate with inactive disease [7]. Further-
more two recent works identified, by microarray and Real
Time PCR assays, 16 and 17 microRNAs differentially
expressed in OA compared to normal cartilage [9,15]. The
problem is that both studies tested the expression of a small
number of miRNAs, in particular 365 and 157 miRNAs re-
spectively, of the total 1,048 different mature microRNAs
identified in humans and recently released by the Sanger
miRBase (release 16.0, September 2010) [26], although
many more miRNAs are still to be identified. Also, contra-
dictory results were postulated in these two recent studies.
In this sense, Jones et al. [9] demonstrated that miR-25 is
upregulated in OA chondrocytes whereas Iliopoulos et al.
[15] stated that this miRNA was downregulated in OA car-
tilage. In the present study, to better understand
the molecular mechanisms involved in the pathogenesis of
OA, we identify and characterize the expression profiles of
723 human miRNAs from normal and OA chondrocytes,
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Methods
Harvest of human cartilage and isolation of chondrocytes
Human cartilage samples, four healthy donors (3 males
and 1 female with a mean age of 68 years and a range from
58 to 79 years) with a Mankin score of 1, and six III and IV
grade OA donors (4 males and 2 females with a mean age
of 64 years and a range from 42 to 80 years) with a Mankin
score of 10 (additional file 1), were provided by the Aut-
opsy Service and the Orthopaedic Department at Hospital
Universitario A Coruña, Spain. These samples came from
patient who underwent replacement surgery or limb
amputations. This study was approved by the Ethic Com-
mittee of Clinical Investigation of Galicia, and informed
consent was obtained from all donors.
Cartilage sections were aseptically removed from each
donor, sliced full thickness and washed in Dulbecco´s
modified Eagle´s medium (DMEM) (Gibco, Life Tech-
nologies, Paisley, Scotland) supplemented only with anti-
biotic penicillin (100 units/ml)-streptomycin (100 μg/ml)
(Gibco Invitrogen, USA) as previously described [27].
Briefly, slices were minced with a scalpel and transferred
to a digestion buffer containing 1% trypsin (Sigma, St.
Louis, MO) for 15 min at 37°C until digestion was
complete. The supernatant (without chondrocytes) was
discarded and, after trypsin removal, the trypsinized car-
tilage was incubated in a second digestion buffer con-
taining 2 mg/l of type IV Collagenase (Sigma, St. Louis,
MO) for 12 to 16 h at 37°C overnight. After this time
cells were washed three times with DMEM and centri-
fuged at 200 xg for 10 minutes before being used for
culture. The number of chondrocytes obtained was
counted by a Neubauer Chamber using the 0.4% tripan
blue dye (Sigma, St. Louis, MO) to assess the viability of
the sample.
Chondrocyte culture
Chondrocytes were cultured in a 25 cm2 culture flask
with DMEM supplemented with 100 units/ml penicillin,
100 μg/ml streptomycin, 1% glutamine and 10% FBS
(Fetal Bovine Serum) (Gibco, Life Technologies, Paisley,
Scotland) in humidified 5% CO2 atmosphere at 37°C
(Steri-Cult 200 Incubator HEPA class 100, Hucoa
Erlöss). Chondrocytes in first sub-culture (S1) were
employed for micropellet studies.
Micropellet formation
Adherent cells in culture from different donors were
treated with trypsin-EDTA. 5x105 cells were centrifuged
at 200xg for 10 minutes and the cellular aggregate was
cultured in DMEM with 10% FBS for 1 week. The culture
medium was changed every 3–4 days. 5 micropelletswere developed for each of the donors. After 1 week the
micropellets were quickly frozen or embedded in paraffin
or included in OCT freezing medium and subsequently
they were used for RNA isolation or for histological and
immunohistochemical stainings.
Histological and immunohistochemical analyses
For general histological analyses, 4 μm-thick paraffin
sections of micropellets were deparaffinized in xylol,
rehydrated in a graded series of ethanol, and stained
with Hematoxylin-Eosin (HE), Alcian Blue (AB), Safra-
nin O (SO) and Masson´s Trichromic (MT). HE staining
allowed performing a general assessment of the structure
of the micropellets, differentiating the nucleus of the
cells with respect to their cytoplasms and the synthe-
sised extracellular matrix. AB and SO stainings revealed
the presence of proteoglycans. MT staining allowed per-
forming a general assessment of the structure of the
micropellets, as in the HE staining, but also revealing
the presence of collagens.
Frozen sections (4 μm-thick) were incubated with dif-
ferent primary antibodies to detect the presence of colla-
gen types I (Abcam, Spain) and II (BioNova Científica,
Spain), aggrecan C-20 (Santa Cruz Biotechnology Inc.,
Germany) and metalloproteinase 13 (Thermo Fisher Sci-
entific, Spain). The peroxidase/DAB ChemMateTM
DAKO EnVisionTM detection kit (Dako Citomation,
USA) was used to determine antigen-antibody inter-
action. Negative staining controls were achieved by
omitting the primary monoclonal antibody. Samples
were visualized using an optical microscope.
RNA extraction
For aggrecan quantification we used qPCR analysis. Iso-
lation of total RNA, coming from 2 to 3 micropellets
from the same donor, was performed using Trizol Re-
agent (Invitrogen, Spain) according to manufacturer´s
instructions. From each micropellet, 5x105 cells were
obtained for RNA isolation. Total RNA was further pro-
cessed in RT-PCR or stored at −80°C until its use. RNA
integrity was confirmed by 2% agarose gel electrophor-
esis and stained with ethidium bromide. RNA also was
assessed for quantity at 260 nm using a NanoDropTM
spectrophotometer (Thermo Scientific, Spain). A260/
A280 relation was calculated for quality and purity.
For miRNA microarray and miRNA qPCR analyses,
total RNA (including microRNAs) was isolated with mir-
VanaTM miRNA Isolation kit (Applied Biosystems,
Spain), according to manufacturer´s protocol, and ana-
lyzed by the DNA microarray hibridization Service at
CNIO (Centro Nacional de Investigaciones Oncológicas,
Spain). As a rigorous step, and before label reaction,
samples were analyzed by means of a LabChip system
using a 2100 Agilent Bioanalyzer (Agilent Technologies,
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Integrity Number (RIN). This analysis was designed to
reveal the ability of RNA samples for the microarray
hybridization experiment [28].
miRNA microarray
Expression levels of 723 microRNAs (miRNA Sanger
Base release 10.1) were studied using Human miRNA
microarray kit (version 2) (Agilent Technologies, Spain).
Total RNA fraction was used to determine its RIN,
which were in the range of 7.4 to 9.6, by Lab-chip tech-
nology on an Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Spain). 120 ng of total RNA was labelled and
hybridized using the commercial miRNA Microarray
System with miRNA Complete and Hyb Kit (Agilent
Technologies, Spain) by following manufacturer's
instructions. The entire labelled sample was used for the
hybridization reaction which was performed at 55 °C
during 40 hours in a total volumen of 45 μl. Images were
scanned on a G2565CA microarray scanner (Agilent
Technologies, Spain) and quantified using Agilent Fea-
ture Extraction (FE) Software (ver. 10.1.1) (Agilent Tech-
nologies, Spain). Also, microarray data were normalized
and analyzed using Agilent FeatureExtraction (FE) Soft-
ware and GeneSpring GX10 (Agilent Technologies,
Spain). All microarray hybridization experiments and
data analysis were performed by the miRNA expression
profiling Service of CNIO (Madrid, Spain). The sequence
of events involved in the processing of the text raw data
files is thresholding to 1 and normalization [=log (base
2) transformation and 75 percentile shift]. Baseline
transformation has not been performed.
cDNA synthesis
For aggrecan quantification reverse-transcription (RT-
PCR) was performed from 1 μg of total RNA using
SuperScriptTM First-Strand Synthesis System for RT-
PCR (InvitrogenTM, Spain) up to a total volume of 20 μl
in a Thermocycler (Gene Amp PCR System 9700, Ap-
plied Biosystem, Spain). 1 μg of total RNA, 2.5 nM ran-
dom hexamers, 0.5 mM of dNTP mix, and 3 μl of
DEPC-treated water were denatured at 65°C for 5 min-
utes and chilled on ice for at least 1 minute. On the
other hand, 2 μl of 10xRT buffer, 5 mM MgCl2, 0.01 M
DTT, and 40 U of RNaseOUT Recombinant Ribonucle-
ase Inhibitor were mixed, collected by centrifugation,
and incubated at 25°C for 2 minutes. After incubation,
50 U of SuperScriptTM RT were added and incubated at
25°C for 10 minutes, 42°C for 50 minutes and 70°C for
15 minutes in a Thermocycler (Gene Amp PCR System
9700, Applied Biosystem, Spain). Finally, samples were
chilled on ice and incubated with 2 U of RNAse H for
20 minutes at 37°C before proceeding to amplification
the target cDNA.Samples were stored at −20 °C before cDNA target was
amplified. Positive and negative controls were included in
each experiment. RNA extraction, reverse transcription-
PCR assay setup and post reverse transcription-PCR
product analysis were carried out in separate designated
rooms to prevent cross-contamination.
Real-Time Quantitative PCR
PCR amplification of aggrecan mRNA was carried out
using primers and conditions shown in Table 1, on
LightCyclerW 480 Instrument (Roche, Mannheim, Ger-
many) using LightCycler 480 SYBR Green I Master
(Roche, Mannheim, Germany).
An initial activation at 95°C for 5 minutes was fol-
lowed by an amplification target sequence 50 cycles of
95°C for 10 s, 60°C for 10s, and 72°C 7 s were used. For
melting curve analysis 1 cycle of 95°C for 5 s, 70°C for
15 s, and 95°C for 1 s was used. Finally, a cooling step
was used at 40°C for 10 s.
We verified that amplifications and the expected size
of each PCR product were specific. 1.8% agarose gel
electrophoresis of all PCR products revealed a single
band that corresponded to the single-amplified products
as predicted by the melting curve analysis of the PCR.
Each assay was done at least in triplicate and included
marker-positive and marker-negative controls and re-
agent with no template controls.
PCR primers for mRNA amplification were carefully
designed using the web-based ProbeFinder software
(Universal ProbeLibrary Design Center) accessible via
Roche Applied Science home page [29]. PCR primers
have been positioned to span exon-intron boundaries,
reducing the risk of detecting genomic DNA. Primers
were purchased from Roche (Mannheim, Germany).
PCR amplification of microRNAs (hsa-miR-145, hsa-
miR-149, hsa-miR-483-5p, hsa-miR-582-3p, hsa-miR-634
and hsa-miR-641; as annotated in the miRBase ver 10.0
and 11.0) was carried out on the LightCyclerW 480 In-
strument (Roche, Mannheim, Germany) using miRCURY
LNATM microRNA PCR System (Exiqon, Vedbaek, Den-
mark). U6 snRNA was used as endogenous control.
An initial activation at 95°C for 10 minutes was fol-
lowed by an amplification target sequence 60 cycles of
95°C for 10 s and 60°C for 10s were used. For melting
curve analysis 1 cycle of 95°C for 5 s, 60°C for 1 min,
and 97°C for 1 s was used. Finally, a cooling step was
used at 50°C for 20 s. Relative levels of expression were
calculated by the 2-ΔΔCt [30].
DNA Sequencing Analysis
After aggrecan quantification by qPCR, at least one PCR
product coming from each PCR experiment was used as
template DNA in order to verify that amplifications cor-
responded to the aggrecan cDNA. PCR products were
Table 1 Primer sequences, conditions and annealing temperature of PCR assay for aggrecan mRNA amplification
Primers Sequence Length %GC Annealing Temperature Amplicon (bp)
AGG 1 F 5´ GCCTACGAAGCAGGCTATGA 3´ 20 mer 55 60°C 136
AGG 1R 5´ GCACGCCATAGGTCCTGA 3´ 18 mer 61
HPRT 1 F 5´ TGACCTTGATTTATTTTGCATACC 3´ 24 mer 33 60°C 102
HPRT 1R 5´ CGAGCAAGACGTTCAGTCCT 3´ 20 mer 55
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Biosciences, Spain). DNA sequencing was performed in
a reference facility on ABI 3100 (Applied Biosystems,
Spain) using Big Dye terminators. Forward and Reverse
specific primers were used.
Other procedures
Standard procedures for manipulation of nucleic acids
were essentially those of Sambrook et al. [31].
Statistical analysis
All statistical analyses regarding miRNA microarray data
were facilitated, together with the results, by the miRNA
expression profiling Service of CNIO (Madrid, Spain).
The miRNA data were analyzed with the GeneSpring
GX10.0 software. In order to analyze the miRNAs with
differential expression in healthy and OA donors, T test
unpaired was used. For the cluster tree analysis, the k-
means clustering algorithm was performed on all the
samples. The rest of the analyses were performed using
SPSS 17.0 software for Windows, p-values <0.05 were
considered to be statistically significant.
Bioinformatic analyses for mRNA target and molecular
pathway prediction
Putative target genes regulated by the miRNAs differen-
tially expressed in normal and OA chondrocyte micro-
pellets were predicted bioinformatically and combining
the prediction of their supposed targets with the biblio-
graphic information of chondrocyte gene expression. For
this purpose miRanda algorithm and the miRGen data-
base were used. miRanda computes optimal sequence
complementarity between a set of mature microRNAs
and a given mRNA using a weighted dynamic program-
ming algorithm [8]. miRGen is a database that aims to
provide comprehensive information about the position
of human and mouse microRNA coding transcripts and
their regulation by transcription factors, including a
unique compilation of both predicted and experimen-
tally supported data [32]. miRanda and miRGen are
freely available at [33] and [34]. Moreover the TargetS-
can Human resource, which provide miRNA target pre-
dictions based on sequence complementary to target
sites with emphasis on perfect base-pairing in the seed
region and sequence conservation [35], was used. Tar-
getScan is freely available at [36]. These web-basedcomputational tools are based on different algorithms
which are based on several parameters calculated indi-
vidually for each miRNA.
In order to identify molecular pathways potentially
altered by the expression of multiple miRNAs, we used
the DIANA-mirPath web-based computational tool [37],
free available at [38]. The software performs an enrich-
ment analysis of multiple miRNA target genes compar-
ing each set of miRNA targets to all known KEGG
(Kyoto Encyclopedia of Genes and Genomes) pathways
[39]. The combinatorial effect of co-expressed miRNAs
in the modulation of a given pathway is taken into ac-
count by the simultaneous analysis of multiple miRNAs.
The graphical output of the program provides an over-
view of the parts of the pathway modulated by micro-
RNAs, facilitating the interpretation and presentation of
the analysis results.
Results
Evaluation of chondrocyte micropellets of donors using
histological, immunohistochemical and molecular biology
techniques
MicroRNA for the microarray studies were generated by
extracting total RNA from chondrocyte micropellets of
healthy (n = 4) and OA (n = 6) donors. These micropel-
lets were analyzed, prior to RNA isolation, using differ-
ent stainings in order to identify the specific and main
components of the cartilage extracellular matrix. Specif-
ically, we sought to determine the presence of molecules
characteristics of hyaline cartilage, such as proteoglycans
and collagens in general, and type II collagen in particu-
lar. As it is shown in Figure 1, chondrocyte micropellets
from healthy and OA donors showed the typical struc-
ture of a micromass. In each micropellet two areas were
observed; the peripheral zone that was very cellular and
with low extracellular matrix, and the central area that
had a greater amount of extracellular matrix synthesized
by the cells.
Chondrocyte micropellets from healthy samples showed
the presence of collagens, in general, and type II colla-
gen in particular. Moreover, they were negative for
MMP13 and type I collagen immunostainings (data not
shown). Regarding Safranin O stainings, surprisingly all
healthy chondrocyte micropellets from healthy donors
showed absence or weakly presence of proteoglycans by
histochemistry. Due to the limitations of this histological
Figure 1 Evaluation of chondrocyte micropellets of donors using histological, immunohistochemical and molecular biology
techniques. [A] Chondrocyte micropellets from normal and OA donors grown for 7 days in Dulbecco's Modified Eagle Medium (DMEM)
supplemented with 10% FBS. Micropellets were stained with Hematoxylin-Eosin (HE), Alcian Blue (AB) and Masson´s Trichromic (MT).
Immunodetection of type II collagen (Col II) was performed to detect this molecule which is characteristic of hyaline cartilage. [B] Aggrecan
mRNA R.E.L. of healthy and OA chondrocyte micropellets measured by Real-Time Quantitative PCR (mean± S.E.).
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we therefore assessed the presence of aggrecan mRNA by
qPCR. All healthy chondrocyte micropellets from healthy
donors showed amplification of aggrecan mRNA. In this
regard aggrecan mRNA R.E.L. ranged from 4.64 to 26.37
(mean±S.E.: 14.22± 5.41).
On the other hand, chondrocyte micropellets of OA
donors were also positive for alcian blue, Masson´s tri-
chromic and type II collagen stainings whereas they
were negative for MMP13 and type I collagen immunos-
tainings (data not shown). As for the case of healthy
donors, chondrocyte micropellets from OA patients
showed absence or weakly expression of proteoglycans
by histochemistry but by means of qPCR we detected
the presence of aggrecan mRNA in 3 of 6 donors. For
OA chondrocyte micropellets, aggrecan mRNA R.E.L.
ranged from 0 to 31.8 (mean ± S.E.: 7.74 ± 5.27).
MicroRNA profiling of normal and OA chondrocytes
To assess the putative role of miRNAs in OA pathology,
we performed a microarray analysis of six OA chondro-
cyte micropellets along with four normal chondrocytes
micropellets. In order to obtain sufficient quantity of
miRNA for subsequent microarray analysis it was neces-
sary to extract total RNA from chondrocyte micropellets
of healthy and OA donors. Total RNA fraction was usedto determine the RNA Integrity Number (RIN), which
was in the range of 7.4 to 9.6, and to assess RNA con-
centration and rRNA ratio [28 s/18 s] by means of a
bioanalyzer (Figure 2A). Once samples passed this qual-
ity control they were ready to be labelled and hybridized
with the Agilent Human miRNA Microarray version 2.
This microarray allowed us to test the expression of 723
microRNAs in chondrocyte micropellets of healthy and
OA donors. After raw data were processed and normal-
ized, the microRNA profiling of normal and OA chon-
drocytes revealed a few number of miRNAs differentially
expressed in normal and OA chondrocytes. Of the 723
miRNAs immobilized on the microarray only 7 miRNAs,
with a fold-change cut-off >1.5, showed a statistically
significant differential expression (Table 2). Amongst
these 7 human miRNAs, 1 was up-regulated in OA
chondrocytes (hsa-miR-483-5p) and 6 were up-regulated
in normal chondrocytes in comparison to OA chondro-
cytes (hsa-miR-149*, hsa-miR-582-3p, hsa-miR-1227,
hsa-miR-634, hsa-miR-576-5p and hsa-miR-641) (Fig-
ure 2 B and C). In this regard, hsa-miR-576-5p was
down-regulated in OA chondrocyte pellets with the
highest fold (4.74) whereas hsa-miR-483-5p was up-
regulated in OA chondrocyte pellets with 2.44 fold. As it
is shown in Figure 3, cluster tree contains results of K-
means clustering algorithm performed with GeneSpring
Figure 2 BioAnalyser gel profiles of total RNA isolated from chondrocyte micropellets of healthy and OA donors were used to
determine the RIN, RNA concentration and rRNA ratio [A]. Up-regulated microRNAs in OA and normal chondrocyte micropellets [B]. Relative
expression levels of those microRNAs differentially expressed in normal and OA chondrocyte micropellets (p value < 0.1 and a fold-change cut-off
>1.5) by Human miRNA microarray assay (mean± S.E.) [C].
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formed by K-means method, ie, defining that the cluster-
ing should identify two classes (normal and OA; K-
means = 2). The algorithm separated into two main
branches or groups, in this sense it separated in one
cluster all OA chondrocyte micropellet samples and in
the other all normal chondrocyte micropellet samples.
This fast and efficient clustering technique allowed us to
analyze miRNA gene expression data where the most
similar expression profiles were joined together to form
a group. In this regard, the miRNA expression profiles
of all the samples analyzed allowed us to distinguish twoclusters: OA and normal chondrocytes micropellets.
Therefore, these 48 miRNAs could represent valid mar-
kers in discriminating normal versus OA chondrocyte
samples, although the small numbers of samples ana-
lyzed on the miRNA microarray requires further studies.
Real Time Quantitative PCR analyses of miRNAs
differentially expressed in normal and OA chondrocytes
micropellets
We selected the hsa-miR-149, hsa-miR-483-5p, hsa-miR-
582-3p, hsa-miR-634 and hsa-miR-641 differentially
expressed for further quantification using quantitative
Table 2 miRNA differentially expressed in normal (N)
versus OA
miRNA name Sanger Accession Fold Change p value
hsa-miR-483-5p MIMAT0004761 2.44 2.35×10-4
hsa-miR-149* MIMAT0000450 −1.76 2.28×10-3
hsa-miR-582-3p MIMAT0004797 −1.94 3.31×10-4
hsa-miR-1227 MIMAT0005580 −1.80 2.54×10-5
hsa-miR-634 MIMAT0003304 −1.75 7.66×10-4
hsa-miR-576-5p MIMAT0003241 −4.74 6.68×10-4
hsa-miR-641 MIMAT0003311 −2.36 1.71×10-3
Data from microarray analysis of miR expression was used to identify miRNAs
with differential expression in normal versus OA micropellets. Only miRNAs with
a statistically significant (p value<0.1) differential expression and a fold-change
cut-off >1.5 are listed. U Mann–Whitney test without Benjamin-Hochberg
multiple testing corrections were used to compute p values. Fold change gives
the absolute ratio of normalized intensities (no log scale) between the average
intensities of the samples grouped (N versus OA). Positive fold change values
indicate elevated expression in OA micropellets, whilst negative fold change
values indicate elevated expression in normal micropellets.
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http://www.biomedcentral.com/1471-2474/13/144PCR techniques (Figure 4). Because hsa-miR-145 showed
elevated expression in OA chondrocytes, although it was
not statistically significant, and it was previously pub-
lished in the literature to be upregulated, together with
hsa-miR-483, in osteochondromas compared to normal
cartilage [40], we decided to select it for qPCR verifica-
tion. The same comparison conditions were used for the
qPCR analyses as for the microarray experiments. We
compared miRNA expression in normal against OA
chondrocyte micropellets. The total RNA isolated from
the same normal and chondrocyte samples were used
for qPCR. In this regard, hsa-miR-145 and hsa-miR-483-
5p were also up-regulated in OA chondrocyte micropel-
lets, in particular 4.4 and 8.45 fold respectively, according
with the results obtained in the miRNA microarray
analysis. On the other hand, hsa-miR-582-3p, hsa-miR-
641, hsa-miR-149 and hsa-miR634 were down-regulated
in OA chondrocyte micropellets, 3.9, 1.52, 2.6 and 4.03
fold respectively, in agreement with miRNA microarray
data, although there were no statistical significant differ-
ences when comparing the different miRNA R.E.L. in
normal versus OA chondrocyte micropellets (p > 0.05, U
Mann–Whitney test). Therefore, the analysis of selected
miRNAs by qPCR confirmed the microarray results, in-
dicating the quality of the miRNA microarray.
Bioinformatic prediction of putative target mRNA genes
regulated by the miRNAs differentially expressed in
normal and OA chondrocytes micropellets
To pursue the study, we performed a bioinformatic pre-
diction in order to know the putative target genes regu-
lated by all the miRNAs differentially expressed in
normal and OA chondrocyte micropellets. For this pur-
pose the following computational tools were used:miRanda [33], miRGen [34] and TargetScan [36], which
utilize distinct parameters to predict the probability of a
specific miRNA to bind within the 3´-UTR sequence of
a given mRNA gene. All the computational programs
predicted potential target mRNA genes for the 7 miR-
NAs differentially expressed in normal and OA chondro-
cytes micropellets and also for the hsa-miR-145. These
potential mRNA targets were grouped by their function.
Of the 7 miRNAs differentially expressed, and the hsa-
miR-145, the largest number of predicted putative tar-
gets included binding proteins (21 to 25%) except for
the hsa-miR-483-5p whose largest number of putative
targets included enzymes (18%). The number of tran-
scription proteins obtained as putative mRNA targets
regulated by hsa-miR-145, hsa-miR-576-5p and hsa-
miR-1227 were also high (18% to 19%), whereas
secretory, membrane, surface or receptor proteins as
predicted targets regulated by hsa-miR-149, hsa-miR-
483-5p, hsa-miR-582-3p, hsa-miR-634 and hsa-miR-641
were also elevated (15 to 19%). Lower percentages of po-
tential targets were related with cell adhesion, transla-
tion, transporter proteins among others.
In order to obtain a list of pathways likely to be specif-
ically controlled by the miRNAs differentially expressed
in normal and OA chondrocytes micropellets, we per-
formed an in silico analysis of the putative interactions
between the 7 miRNAs (hsa-miR-1227 was not incorpo-
rated in the analysis because it was not included in the
miRNA input list) and the most common signalling
pathways by using the web-based computational tool
named DIANA-miRPath. This computational tool esti-
mates the impact of co-expressed miRNAs in biological
pathways. Figure 5 represents the DIANA-miRPath ana-
lysis based on TargetScan 5 target prediction software. It
shows the number of genes targeted by each miRNA.
The “union” bar in a specific pathway indicates the coor-
dinated downregulation of the pathway by all co-
expressed miRNAs whereas the “intersection” bar
reflects and overview of the cooperative downregulation
of single genes by all of the expressed miRNAs. As it is
shown in the graph, genes potentially interacting with
these miRNAs were found to be involved in TGF-beta,
Wnt, MAPK and mTOR signalling, focal adhesion and
regulation of actin cytoskeleton among others.
Discussion
OA is the most common disease of joints in adults
around the world [41], being the knee OA the most
common type. About one-third of all adults have radio-
logical signs of OA. The likelihood of developing OA
increases with age. The prevalence of OA of the knee
is higher among 70- to 74-year-old. Epidemiological
studies have revealed that there are both endogenous
and exogenous risk factors for OA. The pathogenesis
Figure 3 Cluster tree showing miRNA gene expression data of OA and normal chondrocytes micropellets. T test unpaired (2 K-means on
all samples) with no multiple testing correction was performed.
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http://www.biomedcentral.com/1471-2474/13/144of OA is characterized by the progressive destruction
of articular cartilage. Many factors contribute to the
overall degradation of cartilage observed in OA, either
directly or indirectly by modulating anabolic factors
[14]. The capacity of articular cartilage to repair is very
limited, mainly because it is an avascular tissue [42].
Currently, there are no effective pharmacological treat-
ments to treat OA although some drugs slow its pro-
gression. Surgical treatments are not a way to treat OA
even so they still constitute an important tool in cartil-
age repair of those injuries which if not treated or
repaired properly could inevitably end up producing a
secondary OA.
Some miRNA-related studies on cancers and genetic
diseases are based on their different expression profile inpathologic compared to normal tissues [19,20]. Most of
these studies postulate that differential expression of
candidate miRNAs is a possible approach to investigate
the function of miRNAs in human diseases. In attempt-
ing to understand the biological pathways and processes
that underlie the pathogenesis and progression of OA,
genomic approaches have identified miRNAs genes asso-
ciated with cartilage development and homeostasis,
extracellular matrix components and IL-1 signal trans-
duction pathway among others [11,14,43,44]. Tissue
miRNAs have been noted not only as key molecules in
intracellular regulatory networks for gene expression,
but also as biomarkers for various pathological condi-
tions [45]. For example, the expression of miR-146 has
been shown to be intensely expressed in low grade OA
Figure 4 Quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis was performed to quantify hsa-miR-145 and
microRNAs differentially expressed in normal and OA chondrocyte micropellets (mean± S.E.). For this analysis 4 healthy and 6 OA samples
were used.
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http://www.biomedcentral.com/1471-2474/13/144cartilage, indicating that it might play a role in OA car-
tilage pathogenesis [12]. In addition, it has been demon-
strated that miR-27b regulates the expression of MMP13
(Matrix Metalloproteinase 13) in human OA chondro-
cytes, suggesting that up-regulation of miR-27b in vivo
would represent a novel therapeutic approach in OA
[44]. In recent years, a putative role for miR-140 in the
pathogenesis of OA was evidenced [11,14,43], since its
expression is significantly reduced in OA tissue and that
in vitro treatment of chondrocytes with IL-1ß, a cytokine
involved in the pathogenesis of OA, suppresses miR-140
expression [46]. Recent studies have also demonstrated
that several miRNAs might play a role in OA pathogen-
esis [9,47].
In the present study, to better understand the molecu-
lar mechanisms involved in the pathogenesis of OA and
to investigate a possible role of miRNAs in cartilage-
related genes regulation and OA development, wecomprehensively isolated and analyzed miRNAs of nor-
mal and OA chondrocyte micropellets, using miRNA
microarray analysis. From a technical point of view, it is
difficult to obtain a high number of chondrocytes from
articular cartilage explants. Chondrocytes from a healthy
cartilage represent only the 2% of the total volume of
the cartilage. Therefore it is also complicated obtain
large amounts of RNA, enriched in miRNAs, of excellent
quality to performed the microarrays. This difficulty is
even higher when using OA cartilage samples, since OA
cartilage has a smaller number of cells than the healthy
one. The micropellet model is different to the tissue,
since it allows maintaining the cells in a three-
dimensional position, these cells can synthesize extracel-
lular matrix and allows obtaining a greater number of
chondrocytes. For this reason chondrocytes micropellets,
and not the cartilage explants, were employed for miR-
NAs isolation.
Figure 5 DIANA-miRPath in silico analysis showing the genes targeted by the hsa-miR-145 and selected miRNAs grouped by molecular
pathway.
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profiles of 723 human miRNAs from normal and OA
chondrocytes, of which 1 miRNA up-regulated in OA
chondrocyte and 6 were up-regulated in normal chon-
drocyte micropellets. Unsupervised clustering performed
by using processed data from miRNA microarray ana-
lysis highlighted differential expression profiles of 48
miRNAs, interestingly clustering the samples into 2
groups, OA versus normal chondrocyte micropellets.
Therefore these miRNAs could represent valid markers
in discriminating normal versus OA chondrocyte sam-
ples although further studies focused in a large number
of samples should be performed to determine the poten-
tial of these miRNAs for clinical application in the diag-
nosis of OA pathology.
Our profiling results were further validated by the de-
tection of some selected miRNAs by qPCR. Some of
these selected miRNAs (e.g. hsa-miR-145 and hsa-miR-
483-5p) have already been described in the literature
[15,40,48]. Of particular interest was the finding that
hsa-miR-483-5p was up-regulated in OA chondrocyte
micropellets as previously described Iliopoulus et al.,
[15]. In this regard, Iliopoulos et al. [15] reported their
finding of a 16-miRNA OA gene signature from their
studies comparing osteoarthritic and nondiseasedhuman cartilage. These authors found that hsa-miR-483-
5p was upregulated in OA cartilage, not only by miRNA
microarray analysis but also by qPCR techniques. These
findings are in agreement with our miRNA microarray
and qPCR results since we observed an upregulation of
hsa-miR-483-5p in OA chondrocyte micropellets with
the highest fold (8.45) obtained by qPCR. On the other
hand, Zuntini et al. [40] also verified that hsa-miR-145
and hsa-miR-483 are both upregulated in osteochondro-
mas when they are compared to normal cartilage. A re-
cent study postulated that aberrant expression miR-483-
5p together with miR-195 allow the identification of a
subset of poorer prognosis adrenocortical carcinomas
[49]. Moreover, Patterson et al. [50] found that the high
expression of miR-483-5p appears to be a defining char-
acteristic of adrenocortical malignancies, indicating that
it can thus be used to accurately distinguish between be-
nign and malignant adrenocortical tumors. However
Dunn et al. [48], profiling miRNA expression in bovine
articular cartilage, found that hsa-miR-145 were down-
regulated in monolayers of tissue cultured chondrocytes
as compared with levels determined directly from intact
native cartilage. Our microarray analyses showed that
the relative expression levels for hsa-miR-145 were
−2.87 for healthy and 1.85 for OA samples. Moreover,
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http://www.biomedcentral.com/1471-2474/13/144qPCR experiments showed that this miRNA was also up
regulated in OA donors, in particular 4.4 fold. However
neither the microarray nor the qPCR results achieve the
statistical significance previously published in the litera-
ture. Perhaps it could be due to the use of different
microarray technologies, or to the use of cultured cell
instead of tissue samples.
In our study miR-149* was down regulated in OA
chondrocyte micropellets, in agreement with a recent
study published by Jones et al. [9]. These authors, study-
ing the expression profiles of 157 human miRNA, identi-
fied 17 differentially expressed miRNAs in human OA in
comparison to normal cartilage and they determined
their relevance to chondrocyte function. In this sense,
they postulated that miR-149 was downregulated in OA
cartilage, this result is in agreement with our miRNA
microarray analysis regarding miR-149, which was also
downregulated in OA chondrocyte micropellets.
In previous reports hsa-miR-140 was down regulated
and hsa-miR-146 was up regulated in OA cartilage
[9,12,15]. In our study, the expression levels of hsa-miR-
140 and hsa-miR-146 in the microarray analyses showed
no statistical significant differences when comparing
healthy and OA samples. However, hsa-miR-140 showed
a tendency to be down regulated in OA and hsa-miR-
146 showed a tendency to be up regulated in this path-
ology. Such discrepancies found among our results and
those published on the literature could be due to the use
of different microarray technologies, or to the use of cul-
tured cell instead of tissue samples, or to the use of OA
samples obtained from the different zones of the
cartilage.
It is noteworthy that some of the miRNAs differen-
tially expressed in chondrocyte that we identified in our
study are novel as compared with those identified and
published in the literature, e.g. hsa-miR-576-5p, hsa-
miR-582-3p, hsa-miR-634, hsa-miR-641, hsa-miR-1227,
suggesting that they may therefore represent new targets
in articular cartilage.
The key molecular pathways potentially altered by the
miRNAs differentially expressed in normal and OA
chondrocyte micropellets, as predicted by the DIANA-
mirPath web-based computational tool, include TGF-
beta, Wnt, MAPK and mTOR signalling, focal adhesion
and regulation of actin cytoskeleton among others.
These results should be considered since Wnt signalling
pathway has a role in OA pathology [51,52]. In particu-
lar these pathways are key inducers and regulators of
joint development, and are involved in formation of
bone, cartilage and also synovium [53]. For these reasons
Wnt-family of proteins and signalling pathways are at-
tractive targets for OA therapy. In this sense, products
of the Wnt, frizzled, secreted frizzled-related protein
(sFRP), Dickkopf and LDL-receptor-related protein genefamilies have crucial roles in the development and main-
tenance of bone, cartilage and joints [54]. In this sense,
genes of the Wnt pathway are upregulated in the OA bone,
suggesting their involvement not only in cartilage distortion
but also in subchondral bone changes [55]. On the other
hand, TGF-beta 1 induces cartilage extracellular matrix
synthesis and tissue inhibitor of metalloproteinases-3
(TIMP-3), an important natural inhibitor of matrix metallo-
proteinases, aggrecanasses and TNF-alpha-converting en-
zyme, which are implicated in cartilage degradation and
joint inflammation [56]. Moreover, genes belonging to the
TGF-beta signalling pathway, which are supposedly tar-
geted by the miRNAs differentially expressed in our work,
regulate the chondrocyte differentiation and potentially the
OA development [57]. Also, TGF-beta pathway regulates
the expression of the superficial zone protein (SZP) in the
superficial zone chondrocytes, protein implicated in the lu-
brication of the articular cartilage surface [58].
Conclusions
Our potential miRNAtarget predictions and the signal-
ling cascades (previously published in the literature to
be involved in development, maintenance degradation of
cartilage) altered by the differentially expressed miRNAs
supports the potential involvement of the detected miR-
NAs in OA pathology. Taken together, we identified 7
miRNAs differentially expressed in normal and OA
chondrocyte micropellets whose expression profiling
may provide a useful clue for the pathophysiology re-
search of OA. Due to the importance of miRNA in me-
diating the translation of target mRNA into protein, the
identification of miRNA differentially expressed in nor-
mal and OA chondrocyte micropellets we report in this
work could have important diagnostic and therapeutic
potential. The study of miRNAs may lead to finding
novel methods to diagnosis, treat and prevent OA. Fur-
ther studies are needed to know the function of these
miRNAs including the search of their target mRNA
genes, which could lead to the development of novel
therapeutic strategies for the OA treatment.
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